Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Labs

This article was originally published in The Gray Sheet

Executive Summary

Michael Beatrice named VP-corporate and regulatory science, effective Nov. 1. Beatrice, who has 25 years of regulatory affairs experience having previously held positions in FDA's drugs and biologics centers, could prove valuable in upcoming discussions with the agency about recent compliance problems in the firm's diagnostics division (1"The Gray Sheet" Oct. 4, p. 16). Meanwhile, Abbott acquisition target Perclose has postponed to Nov. 19 its shareholders meeting to consider the combination, citing the uncertainty of the outcome of Abbott's discussions with FDA

You may also be interested in...



Abbott Facing FDA Consent Decree Over Alleged QSR Violations

Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.

AAM Urges Supreme Court To Uphold Inter Partes Review

The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.

Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel